MedTech growth concerns likely to overshadow Q3 results, Leerink says
BUZZ-MedTech growth concerns likely to overshadow Q3 results, Leerink says ** Leerink Partners says it remains cautious about the MedTech sector ahead of Q3 earnings, citing a "somewhat murky" near-term backdrop
** Points to growing competition in certain markets, including cardiac devices and diabetes care, uncertain procedure volumes amid higher costs, weakening consumer sentiment and hospital budget pressure from rising interest rates
** "We suspect that even positive 3Q results in isolation could be overshadowed by lingering concerns regarding the earnings and growth backdrop for 2027 and beyond," brokerage says
** Says company-specific catalysts can help Medtronic MDT.N, Tandem Diabetes Care TNDM.O outperform broader sector headwinds
** Most cautious on PROCEPT BioRobotics PRCT.O and Insulet PODD.O, as slowing adoption trends and rising competition could lead to downward revisions to 2027 expectations, brokerage says
(Reporting by Siddhi Mahatole)